sanofi - corporate presentation
Post on 05-Aug-2015
6.140 Views
Preview:
TRANSCRIPT
2015 I CORPORATE PRESENTATION
HOPE, it’s what Sanofi brings each day, responding to the new challenges of protecting the health of seven billion people
VIDEO HOPE
© Denis FelixJune 11, 2015
SANOFI AT A GLANCEOUR HERITAGE
OUR STRATEGY
OUR COMMITMENTS
OUR 3 BUSINESS SEGMENTS
OUR INNOVATION IN R&D
OUR RESPONSIBILITY
OUR KEY FIGURES
OUR PRESENCE
CORPORATE PRESENTATION – JUNE 11, 2015 2
SANOFI AT A GLANCE
OUR HERITAGE
A long tradition in health
4
HoechstMarion Roussel
1997
Roussel1911
Marion1950
Hoechst1863
Synthélabo1970
Delalande1924
Delagrange1931
Robert & Carrière
1901
Dausse1834
BMP Sunstone, Medley,Merial, Nepentes, Zentiva,
Kendricks, Oenobiol, Chattem, Acambis, Symbion, Shantha Biotechnics , Fovea, Bipar
Sciences, Targegen, Genfar, Globalpharma
2008-2015
Genzyme2011
Sanofi-aventis2004
Aventis1999
Sanofi-Synthélabo1999
Sanofi Pasteur2004
Sterling1901
Midy1718
Clin Midy1971
Chinoin1919
Sanofi1973
Connaught1922
Rorer1910
Rhône-Poulenc Rorer1990
Institut Mérieux
1897
Wittman & Poulenc
1860
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
OUR STRATEGY
5
SEIZEVALUE-ENHANCINGGROWTH OPPORTUNITIES
ADAPTSTRUCTURE FORFUTURE CHALLENGES & OPPORTUNITIES
BRINGINNOVATIVE PRODUCTSTO MARKET
Delivering sustainable long-term growth by:
GROWA GLOBAL HEALTHCARELEADER WITH SYNERGISTIC PLATFORMS
© Guillaume Ramon/Capa Pictures
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
6
Our missionWe act with our partner to protect health, enhance life and respond to the hopes and potential healthcare needs of 7 billion people around the world.
3 business segments
Pharma Human vaccines
Animal Health
3 CommitmentsExploring the boundaries of medical innovation for patients
Preventing disease and supporting patients
Improving access to healthcare
More than
110,000employees
Present in
100countries
€33.8 bnIn sales 2014
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
OUR MISSION
We act with our partners to protect health, enhance life, provide hope and respond to the potential healthcare needs of 7 billion people around the world.
With our global footprint and commitment to improving access to medicines and healthcare, we work tirelessly to make a difference to people’s lives every day and transform scientific innovations into therapeutic solutions for patients.
7
© G. Blonsky/Capa Pictures
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
OUR COMMITMENTS
8
1
EXPLORING THE BOUNDARIES OF MEDICAL INNOVATION
Sanofi is committed to a more open and productive Research & Development model, focused on patient needs and based on biotechnology. This model significantly accelerates the pace and enhances the productivity of research, driving the development of more effective health solutions in major therapeutic areas.
Between 2014 and 2020, more than 18 potential launches are anticipated.
© Pierre-Olivier/Capa Pictures
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
OUR COMMITMENTS
9
2
PREVENTING DISEASES AND SUPPORTING PATIENTS
Improved quality of life and longer life expectancy, coupled with increased prevalence of chronic disease are contributing to the evolution of today’s main healthcare challenges.
Sanofi promotes prevention through vaccination and support for patients.
The Group’s commitment goes beyond a medication: it is based on understanding and listening to patients to provide integrated health solutions and personalized treatment.
© Pierre-Olivier/Capa Pictures
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
© Denis Felix
OUR COMMITMENTS
10
3
IMPROVING ACCESS TO HEALTHCAREHealthcare needs vary from continent to continent. While the northern hemisphere is marked by an aging population, the southern is characterised by demographic growth, urbanization, and a rise in chronic diseases.
To meet the many different healthcare needs of the seven billion inhabitants of our planet and improve their access to treatment, Sanofi has established a global presence in more than 100 countries, a specific product portfolio for each market and a leadership position in Emerging markets.
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
OUR3 BUSINESS SEGMENTS
11
HUMAN VACCINES>Pediatric vaccines
> Influenza vaccines
>Booster vaccines for adults and adolescents
>Meningitis vaccines
>Vaccines for travelers and endemic areas
ANIMAL HEALTHPHARMA PRODUCTS
>Anti-parasitics
>Anti-infectives
>Anti-inflammatories
>Anti-ulceratives
VACCINES
>Foot and mooth disease
>Rabies and pets vaccines Range
>Avian vaccines
PHARMA
>Diabetes
>Cardiovascular disease
>Rare diseases
>Multiple sclerosis
>Oncology
>Consumer Health care
>Generics
Net sales€27,720 M
Net sales€3,974 M
Net sales€2,076 M
© G. Blonsky/Capa Pictures
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
OUR INNOVATION IN R&D
12
€4.8bnInvested in R&D in 2014
5R&D HUBS Across Europe, North America and Asia-Pacific
43molecules and vaccines in the R&D portfolio including 14 in late stage*
Up to 18 launches expected between 2014 and 2020
*Annual results, Feb. 2015
Diabetes ToujeoAfrezzaLixilan
LyxumiaInsulin pro
Uncontrolled Hypercholesterolemia
Praluent®
PediatricVaccines
Shan 5PR5i-6-1
Rotavirus vaccine
Rare diseaseFamilial amyloidpolyneuropathy
Patisiran
Dengue Dengue vaccine
Clostridum Difficile C.Diff vaccine
Multiple Sclerosis Lemtrada
Oncology SAR650984
Type 1 Gaucher disease
Cerdelga
Severe asthma dupilumab
Dogs Fleas and ticks Nexgard®
Rheumatoid arthritis sarilumab
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
CORPORATESOCIALRESPONSIBILITY
13
© Pierre–Olivier/Capa Pictures
Each day, across the globe, Sanofi’s 110,000 employees are working to protect the health and improve access to healthcare for as many patients as possible.
As a healthcare company, Sanofi places quality, safety, ethics, and respect for the planet at the heart of its business.
More than300 access to healthcare programs in more than 80 countries
1/3 of the global population has no access to healthcare
More than190 millionpeople benefited
PARTNERING TO PROMOTE ACCESS TO HEALTHCARE
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
14
Improve access to medicines in the most deprived countries with an access to medicines department whose holistic approach acts on several levels:
> Tiered-pricing for affordable medicines
> Information, training and education programs
> Innovative research
> Partnerships on the ground to ensure program success
Reduce health inequalitiesthrough its ’programs dedicated to:
> Childhood cancer
> Maternal and neonatal mortality
> Access to healthcare for the world’s most needy communities.
Promoting quality care by fighting against counterfeit medicines.
CORPORATESOCIALRESPONSIBILITY
© Rémi DUHAMEL - Image in Production
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
OURKEY FIGURES 2014
15
BY ACTIVITIES(in million euros)
BY GEOGRAPHICAL AREA(in million euros)
EMPLOYEES BY ACTIVITIES
EMPLOYEES BY GEOGRAPHICAL AREA
€33.8 bnNet sales
Animal Health2,076
Pharma27,720
Vaccines3,974
More than
110,000employees worldwide
United States11,339
Other countries3,219
Emerging markets11,347
Western Europe7,865
Animal Health6,109
Pharma93,393
Vaccines13,994
Other countries41,528
North America18,627Europe
53,341
Emerging Markets: The world excluding the United States, Canada, Western Europe, Japan, Australia and New Zealand.
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
OUR PRESENCE
16
In more than 100 countries
107Industrial sitesin 40 countries
More than
20R&D sites worldwide
CLOSER TO OUR PATIENTS AND PARTNERS
EUROPE48
Manufacturing sites6
Development centers33
Distribution HubsNORTH AMERICA
19 Manufacturing sites
2 Development centers
8 Distribution Hubs
ASIA-PACIFIC20
Manufacturing sites5
Development centers30
Distribution Hubs
LATIN AMERICA12
Manufacturing sites3
Development centers30
Distribution Hubs
AFRICA-MIDDLE-EAST8
Manufacturing sites1
Development center58
Distribution Hubs
CORPORATE PRESENTATION – JUNE 11, 2015
RECOMMENDATIONS
Forward Looking Statements
This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
17
This corporate presentation is available for all employees of the Sanofi Group. It may be used internally or externally for presentations of the Group, either in whole or in part, as needed.
The information is taken from Sanofi’s annual report on Form 20-F 2014, annual results 2014 and press releases.
Further information is available on www.sanofi.com
CORPORATE PRESENTATION – JUNE 11, 2015
top related